Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 104 results.
LastUpdate Updated on 24/10/2026 [09:02:00]
pdfxls
Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
previousPage Results 100 to 104 of 104  

Anti-TREM-1 antibodies and uses thereof

Publication No.:  CN122303417A 30/06/2026
Applicant: 
BRISTOL MYERS SQUIBB CO
\u767E\u65F6\u7F8E\u65BD\u8D35\u5B9D\u516C\u53F8
CN_122303417_A

Absstract of: CN122303417A

The present invention relates to anti-TREM-1 antibodies and uses thereof, and provides methods of identifying a subject suitable for treatment with an anti-TREM-1 antibody, i.e., an antagonistic anti-TREM-1 antibody, comprising measuring the expression level of a TREM-1 related gene. Also disclosed herein are methods of determining the efficacy of an anti-TREM-1 antibody, comprising measuring the expression level of a TREM-1-related gene. Also disclosed are methods of identifying non-responders to care treatment criteria and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody.

抗ToH1抗体及びその使用の方法

Publication No.:  JP2026521446A 30/06/2026
Applicant: 
ザクリーヴランドクリニックファウンデーション
JP_2026521446_A

Absstract of: WO2024254399A2

The present disclosure relates to anti-ToH1 antibodies, methods of generating anti-ToH1 antibodies, and methods of use of anti-ToH1 antibodies for diagnosis and treatment of microbial disease and/or chronic inflammatory disease, including microbial infection and microbe-associated chronic inflammatory conditions.

Macrophage stimulating 1 receptor (mst1r) variants and uses thereof

Publication No.:  NZ785937A 26/06/2026
Applicant: 
REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS INC.
WO_2021030358_A1

Absstract of: NZ785937A

Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein. Patients heterozygous or homozygous for an MST1 variant nucleic acid molecule encoding Arg651STOP are treated by administration of an MST1 protein.

Label-free cell screening model of GPR183 receptor and application of label-free cell screening model in preparation of drugs

Nº publicación: CN122278770A 26/06/2026

Applicant:

GANJIANG TRADITIONAL CHINESE MEDICINE INNOVATION CENTER
\u8D63\u6C5F\u4E2D\u836F\u521B\u65B0\u4E2D\u5FC3

CN_122278770_PA

Absstract of: CN122278770A

The invention relates to a method for screening drugs for diseases closely related to unmarked G-protein coupled receptors (GPCR), in particular to an unmarked cell screening model of a GPR183 receptor and application of the unmarked cell screening model in preparation of drugs. And the unmarked cell screening model is a stably transfected cell strain CHO-K1-GPR183 with high expression of a GPR183 receptor. The GPR183 receptor stimulant compound N-demethylated nuciferine is obtained by screening through the GPR183 cell screening model established in the invention. At present, researches show that the GPR183 receptor is closely related to the occurrence and development of neuroinflammation/autoimmune diseases such as multiple sclerosis, colitis, type I diabetes and arthritis, cancers and metabolic diseases, so that a seedling compound can be provided for the development of medicines for related diseases.

traducir